Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia.
Rubinstein, JD; Krupski, C; Nelson, AS; O'Brien, MM; Davies, SM; Phillips, CL.
Biology of Blood and Marrow Transplantation.
2020;
26:e280-e285.
Genomic variants of cytarabine sensitivity associated with treatment-related mortality in pediatric AML: A report from the children's oncology group.
Phillips, CL; Lane, A; Gerbing, RB; Alonzo, TA; Wilkey, A; Radloff, G; Lange, B; Gamazon, ER; Dolan, ME; Davies, SM.
Clinical Cancer Research.
2020;
26:2891-2897.
Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities.
Rubinstein, JD; Nelson, AS; Krupski, C; O'Brien, W; Taylor, JM; Badgett, TC; Huang, M; Davies, SM; Phillips, CL.
Pediatric Blood and Cancer.
2020;
67.
Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.
Keating, AK; Gossai, N; Phillips, CL; Maloney, K; Campbell, K; Doan, A; Bhojwani, D; Burke, MJ; Verneris, MR.
Blood Advances.
2019;
3:1926-1929.
Viral surveillance using PCR during treatment of AML and ALL.
Dixon, SB; Lane, A; O'Brien, MM; Burns, KC; Mangino, JL; Breese, EH; Absalon, MJ; Perentesis, JP; Phillips, CL.
Pediatric Blood and Cancer.
2018;
65:e26752-e26752.
Post-transplant lymphoproliferative disorder after solid-organ transplant in children.
Absalon, MJ; Khoury, RA; Phillips, CL.
Seminars in Pediatric Surgery.
2017;
26:257-266.